首页 > 最新文献

Veterinary and comparative oncology最新文献

英文 中文
Use of Lomustine and Prednisolone as First-Line Treatment in Canine Multicentric Lymphoma. 将洛莫司汀和泼尼松龙作为犬多中心淋巴瘤的一线治疗药物
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1111/vco.12990
Chiara Catalucci, Marco Luigi Bianchi, Elisabetta Treggiari, Marta Pieri, Katja Ruess, Paola Valenti

Multiagent chemotherapy is considered the most effective treatment for canine high-grade lymphoma; however, due to cost and time requirements, single-agent protocols have also been described. The aim of our study was to evaluate the outcome and prognostic factors of dogs affected by multicentric lymphoma treated with lomustine and prednisolone as first-line treatment. Cases of medium-large-cell multicentric lymphoma treated with lomustine and prednisolone were included in the study. Response to therapy, time to progression (TTP), median disease-free interval (MDFI) and median survival time (MST) were retrospectively described. Thirty cases were included. Eleven (36.67%) were T cell, 11 (36.67%) were B cell and 8 (26.66%) had unknown immunophenotype. The overall response rate (RR) was 87%, with 15 patients achieving CR (50%) and 11 patients PR (37%). The median TTP, MDFI and MST were 42, 63 and 90 days, respectively. The only factor significantly associated with MDFI and MST was the stage. Dogs with multicentric lymphoma treated with lomustine and prednisolone have lower RR, TTP, MDFI and MST compared with dogs receiving multiagent protocols. Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation.

多药化疗被认为是犬高级淋巴瘤最有效的治疗方法;然而,由于成本和时间要求,也有描述单药方案的。我们的研究旨在评估以洛莫司汀和泼尼松龙作为一线疗法的多中心淋巴瘤患犬的疗效和预后因素。研究对象包括接受洛莫司汀和泼尼松龙治疗的中大细胞多中心淋巴瘤病例。对治疗反应、进展时间(TTP)、中位无病间隔时间(MDFI)和中位生存时间(MST)进行了回顾性描述。研究共纳入 30 个病例。11例(36.67%)为T细胞,11例(36.67%)为B细胞,8例(26.66%)免疫表型不明。总反应率(RR)为87%,其中15名患者达到CR(50%),11名患者达到PR(37%)。中位TTP、MDFI和MST分别为42天、63天和90天。与MDFI和MST明显相关的唯一因素是分期。与接受多药方案治疗的犬相比,接受洛莫司汀和泼尼松龙治疗的多中心淋巴瘤犬的RR、TTP、MDFI和MST均较低。由于反应持续时间较短,本研究证实该方案除了缓解病情外,可能作用甚微。
{"title":"Use of Lomustine and Prednisolone as First-Line Treatment in Canine Multicentric Lymphoma.","authors":"Chiara Catalucci, Marco Luigi Bianchi, Elisabetta Treggiari, Marta Pieri, Katja Ruess, Paola Valenti","doi":"10.1111/vco.12990","DOIUrl":"10.1111/vco.12990","url":null,"abstract":"<p><p>Multiagent chemotherapy is considered the most effective treatment for canine high-grade lymphoma; however, due to cost and time requirements, single-agent protocols have also been described. The aim of our study was to evaluate the outcome and prognostic factors of dogs affected by multicentric lymphoma treated with lomustine and prednisolone as first-line treatment. Cases of medium-large-cell multicentric lymphoma treated with lomustine and prednisolone were included in the study. Response to therapy, time to progression (TTP), median disease-free interval (MDFI) and median survival time (MST) were retrospectively described. Thirty cases were included. Eleven (36.67%) were T cell, 11 (36.67%) were B cell and 8 (26.66%) had unknown immunophenotype. The overall response rate (RR) was 87%, with 15 patients achieving CR (50%) and 11 patients PR (37%). The median TTP, MDFI and MST were 42, 63 and 90 days, respectively. The only factor significantly associated with MDFI and MST was the stage. Dogs with multicentric lymphoma treated with lomustine and prednisolone have lower RR, TTP, MDFI and MST compared with dogs receiving multiagent protocols. Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemical and transcriptomic characterization of T and myeloid cell infiltrates in canine malignant melanoma. 犬恶性黑色素瘤中 T 细胞和骨髓细胞浸润的免疫组织化学和转录组学特征。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-05-16 DOI: 10.1111/vco.12981
Kathryn E Cronise, Jonathan Coy, Steven Dow, Marlene L Hauck, Daniel P Regan

Immune checkpoint inhibitor therapy can provide significant clinical benefit in patients with certain cancer types including melanoma; however, objective responses are only observed for a subset of patients. Mucosal melanoma is a rare melanoma subtype associated with a poor prognosis and, compared with cutaneous melanoma, is significantly less responsive to immune checkpoint inhibitors. Spontaneous canine tumours have emerged as valuable models to inform human cancer studies. In contrast to human melanoma, most canine melanomas are mucosal-an incidence that may be leveraged to better understand the subtype in humans. However, a more comprehensive understanding of the immune landscape of the canine disease is required. Here, we quantify tumour infiltrative T and myeloid cells in canine mucosal (n = 13) and cutaneous (n = 5) melanomas using immunohistochemical analysis of CD3 and MAC387 expression, respectively. Gene expression analysis using the Canine IO NanoString panel was also performed to identify genes and pathways associated with immune cell infiltration. T and myeloid cell densities were variable with geometric means of 158.7 cells/mm2 and 166.7 cells/mm2, respectively. Elevated T cell infiltration was associated with increased expression of cytolytic genes as well as genes encoding the coinhibitory checkpoint molecules PD-1, CTLA-4, TIM-3 and TIGIT; whereas increased myeloid cell infiltration was associated with elevated expression of protumourigenic cytokines. These data provide a basic characterization of the tumour microenvironment of canine malignant melanoma and suggest that, like human melanoma, inherent variability in anti-tumour T cell responses exists and that a subset of canine melanomas may respond better to immunomodulation.

免疫检查点抑制剂疗法可为包括黑色素瘤在内的某些癌症类型患者带来显著的临床获益;然而,只有一部分患者能观察到客观反应。粘膜黑色素瘤是一种罕见的黑色素瘤亚型,预后较差,与皮肤黑色素瘤相比,对免疫检查点抑制剂的反应明显较弱。自发性犬肿瘤已成为人类癌症研究的重要参考模型。与人类黑色素瘤不同的是,犬黑色素瘤大多为粘膜瘤--这种发病率可用于更好地了解人类黑色素瘤的亚型。然而,我们需要更全面地了解犬类疾病的免疫状况。在这里,我们分别使用 CD3 和 MAC387 表达的免疫组化分析方法对犬粘膜(13 例)和皮肤(5 例)黑色素瘤中的肿瘤浸润性 T 细胞和髓细胞进行了量化。还使用犬 IO NanoString 面板进行了基因表达分析,以确定与免疫细胞浸润相关的基因和通路。T 细胞和骨髓细胞密度各不相同,几何平均数分别为 158.7 个细胞/mm2 和 166.7 个细胞/mm2。T细胞浸润的增加与细胞溶解基因以及共同抑制检查点分子PD-1、CTLA-4、TIM-3和TIGIT的编码基因的表达增加有关;而髓样细胞浸润的增加与原发肿瘤细胞因子的表达增加有关。这些数据提供了犬恶性黑色素瘤肿瘤微环境的基本特征,并表明与人类黑色素瘤一样,抗肿瘤 T 细胞反应也存在固有的变异性,而且犬黑色素瘤亚群可能对免疫调节反应更好。
{"title":"Immunohistochemical and transcriptomic characterization of T and myeloid cell infiltrates in canine malignant melanoma.","authors":"Kathryn E Cronise, Jonathan Coy, Steven Dow, Marlene L Hauck, Daniel P Regan","doi":"10.1111/vco.12981","DOIUrl":"10.1111/vco.12981","url":null,"abstract":"<p><p>Immune checkpoint inhibitor therapy can provide significant clinical benefit in patients with certain cancer types including melanoma; however, objective responses are only observed for a subset of patients. Mucosal melanoma is a rare melanoma subtype associated with a poor prognosis and, compared with cutaneous melanoma, is significantly less responsive to immune checkpoint inhibitors. Spontaneous canine tumours have emerged as valuable models to inform human cancer studies. In contrast to human melanoma, most canine melanomas are mucosal-an incidence that may be leveraged to better understand the subtype in humans. However, a more comprehensive understanding of the immune landscape of the canine disease is required. Here, we quantify tumour infiltrative T and myeloid cells in canine mucosal (n = 13) and cutaneous (n = 5) melanomas using immunohistochemical analysis of CD3 and MAC387 expression, respectively. Gene expression analysis using the Canine IO NanoString panel was also performed to identify genes and pathways associated with immune cell infiltration. T and myeloid cell densities were variable with geometric means of 158.7 cells/mm<sup>2</sup> and 166.7 cells/mm<sup>2</sup>, respectively. Elevated T cell infiltration was associated with increased expression of cytolytic genes as well as genes encoding the coinhibitory checkpoint molecules PD-1, CTLA-4, TIM-3 and TIGIT; whereas increased myeloid cell infiltration was associated with elevated expression of protumourigenic cytokines. These data provide a basic characterization of the tumour microenvironment of canine malignant melanoma and suggest that, like human melanoma, inherent variability in anti-tumour T cell responses exists and that a subset of canine melanomas may respond better to immunomodulation.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pilot study to evaluate isolation by size of circulating tumour cells in canine oral melanoma. 评估犬口腔黑色素瘤循环肿瘤细胞大小分离的试点研究。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-04 DOI: 10.1111/vco.12982
Victor Nowosh, Alexcia Camila Braun, Anna Paula Carreta Ruano, Ludmilla Thomé Domingos Chinén, Cristina de Oliveira Massoco

Liquid biopsy for circulating tumour cell (CTC) detection is generally unexplored in veterinary medicine. Dogs with highly aggressive and heterogeneous tumours, such as oral malignant melanoma (OMM), could benefit from studies involving size-based isolation methods for CTCs, as they do not depend on specific antibodies. This pilot study aimed to detect CTCs from canine OMM using Isolation by Size of Epithelial Tumor Cells (ISET), a microfiltration methodology, followed by immunocytochemistry (ICC) with Melan-A, PNL2, and S100 antibodies. Ten canine patients diagnosed by histopathology and confirmed as OMM by immunohistochemistry were enrolled, their prognostic data was assessed, and blood samples were collected for CTC analysis. Results have shown the detection of intact cells in 9/10 patients. ICC has shown 3/9 Melan-A-positive, 3/9 PNL2-positive, and 8/9 S100-positive patients, confirming the importance of opting for a multimarker assay. A significant number of negative-stained CTCs were found, suggesting their high heterogeneity in circulation. Microemboli stained with either PNL2 or S100 were found in a patient with a high isolated cell count and advanced clinical stage. Preliminary statistical analysis shows a significant difference in CTC count between patients with and without lymph node metastasis (p < .05), which may correlate with tumour metastatic potential. However, we recommend further studies with more extensive sampling to confirm this result. This pilot study is the first report of intact CTC detection in canine OMM and the first application of ISET in veterinary medicine, opening new possibilities for liquid biopsy studies in canine OMM and other tumours.

在兽医领域,用于循环肿瘤细胞(CTC)检测的液体活检技术通常还未得到开发。口腔恶性黑色素瘤(OMM)等具有高度侵袭性和异质性肿瘤的狗可以从基于大小的 CTC 分离方法研究中获益,因为这种方法不依赖于特异性抗体。这项试验性研究的目的是利用微滤方法 "上皮肿瘤细胞大小分离"(ISET)检测犬口腔恶性黑色素瘤的 CTC,然后用 Melan-A、PNL2 和 S100 抗体进行免疫细胞化学分析(ICC)。十名经组织病理学诊断并通过免疫组化确诊为 OMM 的犬类患者被纳入研究,他们的预后数据得到了评估,并被采集血液样本用于 CTC 分析。结果显示,9/10 的患者检测到了完整的细胞。ICC显示3/9的患者Melan-A阳性,3/9的患者PNL2阳性,8/9的患者S100阳性,这证实了选择多标记检测的重要性。发现了大量阴性染色的 CTC,这表明它们在血液循环中具有高度异质性。在一名孤立细胞数量较多且处于临床晚期的患者身上,发现了被 PNL2 或 S100 染色的微栓子。初步统计分析表明,有淋巴结转移和没有淋巴结转移的患者之间的 CTC 数量存在显著差异(p
{"title":"Pilot study to evaluate isolation by size of circulating tumour cells in canine oral melanoma.","authors":"Victor Nowosh, Alexcia Camila Braun, Anna Paula Carreta Ruano, Ludmilla Thomé Domingos Chinén, Cristina de Oliveira Massoco","doi":"10.1111/vco.12982","DOIUrl":"10.1111/vco.12982","url":null,"abstract":"<p><p>Liquid biopsy for circulating tumour cell (CTC) detection is generally unexplored in veterinary medicine. Dogs with highly aggressive and heterogeneous tumours, such as oral malignant melanoma (OMM), could benefit from studies involving size-based isolation methods for CTCs, as they do not depend on specific antibodies. This pilot study aimed to detect CTCs from canine OMM using Isolation by Size of Epithelial Tumor Cells (ISET), a microfiltration methodology, followed by immunocytochemistry (ICC) with Melan-A, PNL2, and S100 antibodies. Ten canine patients diagnosed by histopathology and confirmed as OMM by immunohistochemistry were enrolled, their prognostic data was assessed, and blood samples were collected for CTC analysis. Results have shown the detection of intact cells in 9/10 patients. ICC has shown 3/9 Melan-A-positive, 3/9 PNL2-positive, and 8/9 S100-positive patients, confirming the importance of opting for a multimarker assay. A significant number of negative-stained CTCs were found, suggesting their high heterogeneity in circulation. Microemboli stained with either PNL2 or S100 were found in a patient with a high isolated cell count and advanced clinical stage. Preliminary statistical analysis shows a significant difference in CTC count between patients with and without lymph node metastasis (p < .05), which may correlate with tumour metastatic potential. However, we recommend further studies with more extensive sampling to confirm this result. This pilot study is the first report of intact CTC detection in canine OMM and the first application of ISET in veterinary medicine, opening new possibilities for liquid biopsy studies in canine OMM and other tumours.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distribution of Inflammatory Infiltrate in Feline Mammary Lesions: Relationship With Clinicopathological Features. 猫科动物乳腺病变中炎性浸润的分布:与临床病理特征的关系
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-11 DOI: 10.1111/vco.12987
Joana Rodrigues-Jesus, Ana Canadas-Sousa, Pedro Oliveira, Ana Catarina Figueira, Carla Marrinhas, Gonçalo N Petrucci, Hugo Gregório, Flora Tinoco, Andrea Goulart, Helena Felga, Hugo Vilhena, Patrícia Dias-Pereira

Inflammation is a frequent finding in feline mammary neoplasms. Recent research suggests that the presence and location of tumour-associated immune cells might play a significant role in the clinical outcome of feline mammary carcinomas. The present study aimed to characterise the overall inflammatory infiltrates in healthy, hyperplastic/dysplastic, benign and malignant lesions of the feline mammary gland, and to evaluate its association with clinicopathological features. Perilesional and intralesional inflammatory foci were evaluated in 307 lesions from 185 queens, and categorised according to its distribution and intensity. The presence, location and density of tertiary lymphoid structures were also assessed. A control group included 24 queens without mammary changes. The presence of intralesional and perilesional inflammatory infiltrate was observed in a majority of the lesions (80.8% and 90.2%, respectively), but differed according to the type of mammary lesion, being more remarkable in malignant neoplasms. Only scarce individual cells were observed in 28.1% of the normal mammary glands. Data analysis revealed statistically significant associations (p < 0.05) between the presence of a more prominent intralesional and perilesional inflammatory reaction and several clinicopathological features associated with worse prognosis, including clinical stage, tumour size, mitotic count, lymphovascular invasion and lymph node metastasis. Furthermore, tertiary lymphoid structures were significantly more frequent in tumours with an infiltrative growth and lymph node metastasis. According to our results, the inflammatory reaction present in different types of feline mammary lesions is associated with the development of more aggressive tumours.

炎症是猫科动物乳腺肿瘤的常见症状。最近的研究表明,肿瘤相关免疫细胞的存在和位置可能对猫乳腺癌的临床结果起着重要作用。本研究旨在描述猫乳腺健康、增生/发育不良、良性和恶性病变中整体炎症浸润的特征,并评估其与临床病理特征的关联。对来自 185 只猫科动物的 307 个病灶的周围和内部炎症病灶进行了评估,并根据其分布和强度进行了分类。此外,还评估了三级淋巴结构的存在、位置和密度。对照组包括 24 只没有乳腺病变的皇后。在大多数病变(分别为 80.8% 和 90.2%)中都观察到了乳腺内部和周围的炎症浸润,但根据乳腺病变的类型而有所不同,恶性肿瘤中的炎症浸润更为明显。在 28.1%的正常乳腺中仅观察到稀少的单个细胞。数据分析显示,在统计意义上(p
{"title":"Distribution of Inflammatory Infiltrate in Feline Mammary Lesions: Relationship With Clinicopathological Features.","authors":"Joana Rodrigues-Jesus, Ana Canadas-Sousa, Pedro Oliveira, Ana Catarina Figueira, Carla Marrinhas, Gonçalo N Petrucci, Hugo Gregório, Flora Tinoco, Andrea Goulart, Helena Felga, Hugo Vilhena, Patrícia Dias-Pereira","doi":"10.1111/vco.12987","DOIUrl":"10.1111/vco.12987","url":null,"abstract":"<p><p>Inflammation is a frequent finding in feline mammary neoplasms. Recent research suggests that the presence and location of tumour-associated immune cells might play a significant role in the clinical outcome of feline mammary carcinomas. The present study aimed to characterise the overall inflammatory infiltrates in healthy, hyperplastic/dysplastic, benign and malignant lesions of the feline mammary gland, and to evaluate its association with clinicopathological features. Perilesional and intralesional inflammatory foci were evaluated in 307 lesions from 185 queens, and categorised according to its distribution and intensity. The presence, location and density of tertiary lymphoid structures were also assessed. A control group included 24 queens without mammary changes. The presence of intralesional and perilesional inflammatory infiltrate was observed in a majority of the lesions (80.8% and 90.2%, respectively), but differed according to the type of mammary lesion, being more remarkable in malignant neoplasms. Only scarce individual cells were observed in 28.1% of the normal mammary glands. Data analysis revealed statistically significant associations (p < 0.05) between the presence of a more prominent intralesional and perilesional inflammatory reaction and several clinicopathological features associated with worse prognosis, including clinical stage, tumour size, mitotic count, lymphovascular invasion and lymph node metastasis. Furthermore, tertiary lymphoid structures were significantly more frequent in tumours with an infiltrative growth and lymph node metastasis. According to our results, the inflammatory reaction present in different types of feline mammary lesions is associated with the development of more aggressive tumours.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas. 一个健康:针对人类和犬组织细胞肉瘤和树突状细胞肉瘤基因变异的疗法。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1111/vco.12988
Suzanne Agnes Erich, Erik Teske

The precise cause of HS/DCS is still unknown. The relatively low incidence in humans urges for an animal model with a high incidence to accelerate knowledge about genetics and optimal treatment of HS/DCS. Namely, until now, the therapies targeting genetic variants are still more experimental and sparsely used, while consensus is missing. In addition, the literature about variants and possible mutation-targeted therapies in humans and dogs consists mainly of case reports scattered throughout the literature. Therefore, an overview is provided of all currently known genetic variants in humans and dogs with HS/DCS and its subtypes, their possible mutation-targeted therapies, their efficacy, and a contemplation about the future. Several genetic variants have already been discovered in HS/DCS, of which many are shared between canine and human HS/DCS, but unique variants exist as well. Unfortunately, none of these already found variants seem to be specifically causal for HS/DCS, and the puzzle of its landscape of genetic variation is far from complete. The use of mutation-targeted therapies, including MAPK-/MEK-inhibitors and the future use of PTPN11-, CDK4/6- and PD-1-inhibitors, seems to be promising for these specific variants, but clearly, clinical trials are needed to determine optimal inhibitors and standardised protocols for all variants. It can be concluded that molecular analysis for variants and subsequent mutation-targeted therapy are an essential addition to cancer diagnostics and therapy. A joint effort of humans and dogs in research is urgently needed and will undoubtedly increase knowledge and survival of this devastating disease in dogs and humans.

HS/DCS 的确切病因尚不清楚。由于人类的发病率相对较低,因此需要一种发病率较高的动物模型来加速对 HS/DCS 遗传学和最佳治疗方法的了解。也就是说,到目前为止,针对基因变异的治疗方法仍然更多是实验性的,而且很少使用,还没有达成共识。此外,有关人类和狗的变异和可能的基因突变靶向疗法的文献主要是散见于文献中的病例报告。因此,本文概述了目前已知的人类和犬 HS/DCS 基因变异及其亚型、可能的基因突变靶向疗法、其疗效以及对未来的展望。在 HS/DCS 中已经发现了几种基因变异,其中许多变异在犬和人类 HS/DCS 中是共有的,但也存在独特的变异。遗憾的是,这些已发现的变异似乎都不是 HS/DCS 的特定致病因素,而且其基因变异情况的谜团还远未解开。使用突变靶向疗法,包括 MAPK/MEK 抑制剂和未来使用的 PTPN11、CDK4/6 和 PD-1 抑制剂,似乎对这些特定变异很有希望,但显然还需要进行临床试验,以确定针对所有变异的最佳抑制剂和标准化方案。可以得出的结论是,变异的分子分析和随后的突变靶向治疗是癌症诊断和治疗的重要补充。目前迫切需要人类和犬类共同努力开展研究,这无疑将增加人们对这种毁灭性疾病的了解,提高犬类和人类的存活率。
{"title":"One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas.","authors":"Suzanne Agnes Erich, Erik Teske","doi":"10.1111/vco.12988","DOIUrl":"10.1111/vco.12988","url":null,"abstract":"<p><p>The precise cause of HS/DCS is still unknown. The relatively low incidence in humans urges for an animal model with a high incidence to accelerate knowledge about genetics and optimal treatment of HS/DCS. Namely, until now, the therapies targeting genetic variants are still more experimental and sparsely used, while consensus is missing. In addition, the literature about variants and possible mutation-targeted therapies in humans and dogs consists mainly of case reports scattered throughout the literature. Therefore, an overview is provided of all currently known genetic variants in humans and dogs with HS/DCS and its subtypes, their possible mutation-targeted therapies, their efficacy, and a contemplation about the future. Several genetic variants have already been discovered in HS/DCS, of which many are shared between canine and human HS/DCS, but unique variants exist as well. Unfortunately, none of these already found variants seem to be specifically causal for HS/DCS, and the puzzle of its landscape of genetic variation is far from complete. The use of mutation-targeted therapies, including MAPK-/MEK-inhibitors and the future use of PTPN11-, CDK4/6- and PD-1-inhibitors, seems to be promising for these specific variants, but clearly, clinical trials are needed to determine optimal inhibitors and standardised protocols for all variants. It can be concluded that molecular analysis for variants and subsequent mutation-targeted therapy are an essential addition to cancer diagnostics and therapy. A joint effort of humans and dogs in research is urgently needed and will undoubtedly increase knowledge and survival of this devastating disease in dogs and humans.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial. 癌症犬服用曲美替尼的群体药代动力学、药效学和安全性特性:I 期剂量递增临床试验。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1111/vco.12989
Marilia Takada, Keita Kitagawa, Yongzhen Zhang, Jürgen B Bulitta, Steven Moirano, Abigail Jones, Jennifer Borgen, Ashley Onsager, Tuddow Thaiwong, David M Vail

MAPK has been reported as a key oncogenic pathway for canine histiocytic sarcoma, which can be pharmacologically targeted with trametinib, a small inhibitor of MEK1/2. Preliminary data showed promising antitumor activity in in vitro and in vivo models and represented a proof of concept to translate the findings from bench to bedside. In this phase I, dose escalating study using a 3 + 3 cohort design, trametinib was evaluated in 18 dogs with cancer. Adverse events were graded according to VCOG-CTCAE v2. Blood samples and tumour biopsies were collected for pharmacokinetic and pharmacodynamic assessment. Trametinib was well tolerated with a maximum tolerated dose of 0.5 mg/m2/day, PO. Dose-limiting toxicities included systemic hypertension, proteinuria, lethargy and elevated ALP, and were all Grade 3. The drug exposures increased more than linearly with dose since the elimination of trametinib was saturable. At a dose of 500 μg Q24h (0.5 mg/m2/day in a 30 kg dog), approximately 70% of dogs had an average steady-state concentration of 10 ng/mL, achieved after approximately 2 weeks. This threshold was associated with clinical efficacy in humans. Target engagement was not observed in biospecimens collected on Days 0 and 7. In conclusion, trametinib was considered safe in dogs with cancer, and the dose of 0.5 mg/m2/day was the recommended dose for phase II studies.

据报道,MAPK是犬组织细胞肉瘤的一个关键致癌途径,而MEK1/2的一种小型抑制剂曲美替尼可作为药物靶点。初步数据显示,MEK1/2 在体外和体内模型中具有良好的抗肿瘤活性,是将研究成果从实验室转化为临床应用的概念验证。在这项采用 3+3 队列设计的 I 期剂量递增研究中,对 18 只患癌症的狗进行了曲美替尼评估。研究人员根据 VCOG-CTCAE v2 对不良反应进行了分级,并采集了血液样本和肿瘤活检样本用于药代动力学和药效学评估。曲美替尼耐受性良好,最大耐受剂量为0.5毫克/平方米/天,口服。剂量限制性毒性包括全身性高血压、蛋白尿、嗜睡和ALP升高,均为3级。由于曲美替尼的消除是饱和的,因此药物暴露量随剂量的增加而增加,超过了线性关系。在 500 μg Q24h 的剂量下(30 千克犬 0.5 毫克/平方米/天),约 70% 的犬在约 2 周后达到 10 纳克/毫升的平均稳态浓度。这一阈值与人类的临床疗效相关。在第0天和第7天采集的生物样本中未观察到目标参与。总之,在癌症犬中使用曲美替尼是安全的,0.5毫克/平方米/天的剂量是II期研究的推荐剂量。
{"title":"Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial.","authors":"Marilia Takada, Keita Kitagawa, Yongzhen Zhang, Jürgen B Bulitta, Steven Moirano, Abigail Jones, Jennifer Borgen, Ashley Onsager, Tuddow Thaiwong, David M Vail","doi":"10.1111/vco.12989","DOIUrl":"10.1111/vco.12989","url":null,"abstract":"<p><p>MAPK has been reported as a key oncogenic pathway for canine histiocytic sarcoma, which can be pharmacologically targeted with trametinib, a small inhibitor of MEK1/2. Preliminary data showed promising antitumor activity in in vitro and in vivo models and represented a proof of concept to translate the findings from bench to bedside. In this phase I, dose escalating study using a 3 + 3 cohort design, trametinib was evaluated in 18 dogs with cancer. Adverse events were graded according to VCOG-CTCAE v2. Blood samples and tumour biopsies were collected for pharmacokinetic and pharmacodynamic assessment. Trametinib was well tolerated with a maximum tolerated dose of 0.5 mg/m<sup>2</sup>/day, PO. Dose-limiting toxicities included systemic hypertension, proteinuria, lethargy and elevated ALP, and were all Grade 3. The drug exposures increased more than linearly with dose since the elimination of trametinib was saturable. At a dose of 500 μg Q24h (0.5 mg/m<sup>2</sup>/day in a 30 kg dog), approximately 70% of dogs had an average steady-state concentration of 10 ng/mL, achieved after approximately 2 weeks. This threshold was associated with clinical efficacy in humans. Target engagement was not observed in biospecimens collected on Days 0 and 7. In conclusion, trametinib was considered safe in dogs with cancer, and the dose of 0.5 mg/m<sup>2</sup>/day was the recommended dose for phase II studies.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrochemotherapy in dogs and cats-A review. 猫狗的电化学疗法--综述。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1111/vco.12980
Sofia Chichorro Ramos, Patrícia Dias-Pereira, Ana Lúcia Luís, Michael MacFarlane, Andreia Alexandra Santos

Electrochemotherapy (ECT) is a treatment modality that combines the electroporation of cell membranes with chemotherapy to facilitate the transport of non-permeant molecules into cells. Several canine and feline studies have shown promising results, suggesting that ECT can be a valid adjuvant or alternative treatment option for some tumours. The objective of this paper is to provide a bibliographic review of the principles and applications of ECT in veterinary medicine and to compare to its use in human medicine.

电化学疗法(ECT)是一种将细胞膜电穿孔与化疗相结合的治疗方式,可促进非渗透性分子进入细胞。一些犬科和猫科动物的研究结果表明,电化学疗法是治疗某些肿瘤的有效辅助或替代疗法。本文旨在对ECT在兽医学中的原理和应用进行文献综述,并将其与在人类医学中的应用进行比较。
{"title":"Electrochemotherapy in dogs and cats-A review.","authors":"Sofia Chichorro Ramos, Patrícia Dias-Pereira, Ana Lúcia Luís, Michael MacFarlane, Andreia Alexandra Santos","doi":"10.1111/vco.12980","DOIUrl":"10.1111/vco.12980","url":null,"abstract":"<p><p>Electrochemotherapy (ECT) is a treatment modality that combines the electroporation of cell membranes with chemotherapy to facilitate the transport of non-permeant molecules into cells. Several canine and feline studies have shown promising results, suggesting that ECT can be a valid adjuvant or alternative treatment option for some tumours. The objective of this paper is to provide a bibliographic review of the principles and applications of ECT in veterinary medicine and to compare to its use in human medicine.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Three Chemotherapy Protocols With Electrochemotherapy for the Treatment of Feline Cutaneous Squamous Cell Carcinoma. 比较三种化疗方案与电化学疗法治疗猫皮肤鳞状细胞癌的效果
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1111/vco.12995
Nicolas Diop, David Sayag, Grégoire Bernardo Marques, Gabriel Chamel, Thomas Chavalle, Jean-Bapiste Eon, Franck Floch, Mathilde Lajoinie, Frédérique Ponce, Laura E Barrett

Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.

使用静脉注射博莱霉素和/或瘤内注射博莱霉素的电化学疗法(ECT)在治疗不可切除的猫皮肤鳞状细胞癌(cSCC)方面疗效显著,反应率高达95%,但尚未对其他化疗方案进行研究。这项前瞻性多中心研究的目的是比较使用IT和静脉注射卡铂(静脉注射+IT)、静脉注射卡铂(静脉注射)或静脉注射博莱霉素(静脉注射)进行ECT治疗的猫皮肤鳞状细胞癌患者的总反应率(ORR)和无进展间隔时间(PFI)。三个中心共招募了44只无法切除的cSCC猫,并使用卡铂静脉注射+IT(10只)、卡铂静脉注射(11只)或博来霉素静脉注射(23只)进行ECT治疗。根据RECIST标准,在治疗后2周和4周记录治疗反应,并随访患者直至疾病进展和/或死亡。三组患者的年龄、性别、体重和病灶大小相当。三组患者的不良反应一般都比较轻微、局部,且组间情况相似。ORR分别为90.0%(卡铂静脉注射+IT)、90.9%(卡铂静脉注射)和95.6%(博莱霉素静脉注射),无显著差异(p = 0.79)。卡铂静脉注射 + IT 或卡铂静脉注射未达到中位 PFI,博莱霉素静脉注射的中位 PFI 为 566 天,三组之间无显著差异(p = 0.81)。这项研究表明,使用静脉注射或静脉注射+IT卡铂的ECT是治疗cSCC的一种合理的替代疗法,有必要进一步研究比较不同治疗方案的疗效。
{"title":"Comparison of Three Chemotherapy Protocols With Electrochemotherapy for the Treatment of Feline Cutaneous Squamous Cell Carcinoma.","authors":"Nicolas Diop, David Sayag, Grégoire Bernardo Marques, Gabriel Chamel, Thomas Chavalle, Jean-Bapiste Eon, Franck Floch, Mathilde Lajoinie, Frédérique Ponce, Laura E Barrett","doi":"10.1111/vco.12995","DOIUrl":"10.1111/vco.12995","url":null,"abstract":"<p><p>Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of the dissemination of canine cancer misinformation on YouTube. YouTube 上传播犬类癌症错误信息的特点。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-04-28 DOI: 10.1111/vco.12977
Eliza R Richartz, Brittany A Hodgkiss, Noah C Black-Ocken, Rebecca A Fuentes, Jayme S Looper, Sita S Withers

YouTube is the third most popular app in the world and continues to grow each year while it reaches over 2 billion users a month. A variety of veterinary topics are addressed on YouTube but to date there have been no studies analysing misinformation of various canine cancer topics on YouTube or social media. This study described the characteristics of 99 unique videos and used the validated DISCERN quality criteria for consumer health information and the Patient Education Materials Assessment Tool (PEMAT) to characterize their usefulness. The overall median DISCERN quality score was 3 (out of 5), the median PEMAT understandability score was 72%, and 61% of videos contained little to no misinformation. 53% of videos were created by veterinarians and this subset had significantly higher PEMAT understandability and DISCERN quality scores compared with client-created content (p = .0228 and p ≤ .0001, respectively). Videos with little to no misinformation had statistically significant higher DISCERN quality scores (3 vs. 2, p = .0001). There was no statistical significance between misinformation levels and video length, PEMAT understandability, thumbs up/view, or views/mo. These data reveal similar rates of misinformation in videos on canine cancer compared to that reported for various human cancer topics. This study highlights the need for veterinarians to guide clients to more reliable and understandable information regarding their pet's health.

YouTube 是全球第三大最流行的应用程序,并且每年都在持续增长,每月用户数量超过 20 亿。YouTube 上涉及各种兽医话题,但迄今为止还没有研究分析 YouTube 或社交媒体上有关各种犬类癌症话题的错误信息。本研究描述了 99 个独特视频的特征,并使用经过验证的消费者健康信息 DISCERN 质量标准和患者教育材料评估工具 (PEMAT) 来描述这些视频的实用性。DISCERN 质量评分的总体中位数为 3 分(满分 5 分),PEMAT 可理解性评分的中位数为 72%,61% 的视频几乎不包含错误信息。53%的视频由兽医制作,与客户制作的内容相比,这部分视频的PEMAT可理解性和DISCERN质量得分明显更高(分别为p = .0228和p ≤ .0001)。在统计意义上,几乎没有错误信息的视频的 DISCERN 质量得分更高(3 对 2,p = .0001)。错误信息水平与视频长度、PEMAT 可理解性、竖起大拇指/观看次数或观看次数/月之间没有统计学意义。这些数据表明,犬类癌症视频中的错误信息率与各种人类癌症主题视频中的错误信息率相似。这项研究强调,兽医需要引导客户获得更可靠、更易懂的宠物健康信息。
{"title":"Characterization of the dissemination of canine cancer misinformation on YouTube.","authors":"Eliza R Richartz, Brittany A Hodgkiss, Noah C Black-Ocken, Rebecca A Fuentes, Jayme S Looper, Sita S Withers","doi":"10.1111/vco.12977","DOIUrl":"10.1111/vco.12977","url":null,"abstract":"<p><p>YouTube is the third most popular app in the world and continues to grow each year while it reaches over 2 billion users a month. A variety of veterinary topics are addressed on YouTube but to date there have been no studies analysing misinformation of various canine cancer topics on YouTube or social media. This study described the characteristics of 99 unique videos and used the validated DISCERN quality criteria for consumer health information and the Patient Education Materials Assessment Tool (PEMAT) to characterize their usefulness. The overall median DISCERN quality score was 3 (out of 5), the median PEMAT understandability score was 72%, and 61% of videos contained little to no misinformation. 53% of videos were created by veterinarians and this subset had significantly higher PEMAT understandability and DISCERN quality scores compared with client-created content (p = .0228 and p ≤ .0001, respectively). Videos with little to no misinformation had statistically significant higher DISCERN quality scores (3 vs. 2, p = .0001). There was no statistical significance between misinformation levels and video length, PEMAT understandability, thumbs up/view, or views/mo. These data reveal similar rates of misinformation in videos on canine cancer compared to that reported for various human cancer topics. This study highlights the need for veterinarians to guide clients to more reliable and understandable information regarding their pet's health.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of Stereotactic Radiation Therapy Versus Fractionated Radiation Therapy in 44 Dogs With Pituitary Masses: A Multi-Institutional Retrospective Study (2016-2022). 立体定向放射治疗与分次放射治疗在 44 只垂体肿块犬中的疗效:一项多机构回顾性研究(2016-2022年)》。
IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1111/vco.12991
Tracy L Gieger, Leanne Magestro, Jillian Walz, Hiroto Yoshikawa, Michael W Nolan

Although canine pituitary masses (PM) are increasingly treated with stereotactic radiotherapy (SRT), historical literature supports superior outcomes with conventional full-course fractionated radiation therapy (FRT). A multi-institutional retrospective study was performed, including dogs with PM treated from 2016 to 2022 with SRT (total dose 30 or 35 Gy in 5 daily fractions) or FRT (total dose 50-54 Gy in 19-20 daily fractions). The influence of potential prognostic/predictive factors was assessed, including pituitary: brain height, pituitary: brain volume, sex, age and endocrine status (functional [F] vs. nonfunctional [NF] PM). Forty-four dogs with PM were included (26 F, 14 NF, 4 unknown). All patients completed protocols as scheduled (SRT = 27, FRT = 17) and two dogs had suspected Grade 1 acute neurotoxicity. During the first 6 months after RT, 5/27 (19%) dogs treated with SRT (4 F, 1 NF) and 3/17 (18%) dogs treated with FRT (all F) died or were euthanised because of progressive neurologic signs. The overall median survival time was 608 days (95% CI, 375-840 days). Young age at the time of treatment was significant for survival (p = 0.0288); the overall median survival time was 753 days for dogs <9 years of age (95% CI, 614-892 days) and 445 days for dogs ≥9 years of age (95% CI, 183-707 days). Survival time was not associated with treatment type or any other factor assessed herein. A prospective study using standardised protocols would further validate the results of the present study and potentially elucidate the predictors of early death.

尽管犬垂体肿块(PM)越来越多地采用立体定向放射治疗(SRT),但历史文献资料显示,传统的全疗程分次放射治疗(FRT)疗效更佳。我们开展了一项多机构回顾性研究,研究对象包括2016年至2022年期间接受SRT(总剂量30或35 Gy,每天5次分次放疗)或FRT(总剂量50-54 Gy,每天19-20次分次放疗)治疗的垂体瘤犬。评估了潜在预后/预测因素的影响,包括垂体:脑高、垂体:脑容量、性别、年龄和内分泌状态(功能性 [F] PM 与非功能性 [NF] PM)。共纳入了 44 只患有 PM 的狗(26 只 F 型,14 只 NF 型,4 只未知)。所有患者都按计划完成了治疗方案(SRT = 27,FRT = 17),有两只狗出现了疑似一级急性神经毒性。在 RT 治疗后的前 6 个月中,5/27(19%)只接受 SRT 治疗的狗(4 只 F,1 只 NF)和 3/17(18%)只接受 FRT 治疗的狗(均为 F)因出现进行性神经症状而死亡或安乐死。总体中位生存时间为 608 天(95% CI,375-840 天)。接受治疗时年龄较小对存活率有显著影响(p = 0.0288);狗的总存活时间中位数为 753 天。
{"title":"Outcomes of Stereotactic Radiation Therapy Versus Fractionated Radiation Therapy in 44 Dogs With Pituitary Masses: A Multi-Institutional Retrospective Study (2016-2022).","authors":"Tracy L Gieger, Leanne Magestro, Jillian Walz, Hiroto Yoshikawa, Michael W Nolan","doi":"10.1111/vco.12991","DOIUrl":"10.1111/vco.12991","url":null,"abstract":"<p><p>Although canine pituitary masses (PM) are increasingly treated with stereotactic radiotherapy (SRT), historical literature supports superior outcomes with conventional full-course fractionated radiation therapy (FRT). A multi-institutional retrospective study was performed, including dogs with PM treated from 2016 to 2022 with SRT (total dose 30 or 35 Gy in 5 daily fractions) or FRT (total dose 50-54 Gy in 19-20 daily fractions). The influence of potential prognostic/predictive factors was assessed, including pituitary: brain height, pituitary: brain volume, sex, age and endocrine status (functional [F] vs. nonfunctional [NF] PM). Forty-four dogs with PM were included (26 F, 14 NF, 4 unknown). All patients completed protocols as scheduled (SRT = 27, FRT = 17) and two dogs had suspected Grade 1 acute neurotoxicity. During the first 6 months after RT, 5/27 (19%) dogs treated with SRT (4 F, 1 NF) and 3/17 (18%) dogs treated with FRT (all F) died or were euthanised because of progressive neurologic signs. The overall median survival time was 608 days (95% CI, 375-840 days). Young age at the time of treatment was significant for survival (p = 0.0288); the overall median survival time was 753 days for dogs <9 years of age (95% CI, 614-892 days) and 445 days for dogs ≥9 years of age (95% CI, 183-707 days). Survival time was not associated with treatment type or any other factor assessed herein. A prospective study using standardised protocols would further validate the results of the present study and potentially elucidate the predictors of early death.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Veterinary and comparative oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1